Inhibitors targeting S100A8/A9 or IL-17, such as anti-S100A8/A9 antibodies or IL-17 inhibitors (e.g., Secukinumab), may help mitigate immune dysregulation and inflammation in sepsis, offering promising avenues for improved patient outcomes. The gene discussed is S100A8; the disease is Sepsis.